Physician profile
Behice Ozbay
NPI 1548221229
$94.00
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.03 · 2021: $25.12 · 2022: $42.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.85 | 2019-2022 | |
| Lucid Diagnostics INC. | $14.63 | 2022 | |
| Si-Bone, INC. | $14.42 | 2022 | |
| Medtronic, INC. | $13.34 | 2021 | |
| Merck Sharp & Dohme LLC | $11.78 | 2021 | |
| Astellas Pharma US INC | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behice Ozbay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.